Abstract:Genomic loss of the transcriptional kinase occurs in ~6% of metastatic castration-resistant prostate cancers (mCRPC) and correlates with poor patient outcomes. Prior studies demonstrate that acute CDK12 loss confers a homologous recombination (HR) deficiency (HRd) phenotype via premature intronic polyadenylation (IPA) of key HR pathway genes, including . However, mCRPC patients have not demonstrated benefit from therapies that exploit HRd such as inhibitors of polyADP ribose polymerase (PARP). Based on this discordance, we sought to test the hypothesis that an HRd phenotype is primarily a consequence of acute loss and the effect is greatly diminished in prostate cancers adapted to loss. Analyses of whole genome sequences (WGS) and RNA sequences (RNAseq) of human mCRPCs determined that tumors with biallelic alterations ( ) lack genomic scar signatures indicative of HRd, despite carrying bi-allelic loss and the appearance of the hallmark tandem-duplicator phenotype (TDP). Experiments confirmed that acute CDK12 inhibition resulted in aberrant polyadenylation and downregulation of long genes (including and ) but such effects were modest or absent in tumors adapted to chronic . One key exception was , which did retain transcript shortening and reduced protein expression in the adapted models. However, cells demonstrated intact HR as measured by RAD51 foci formation following irradiation. cells showed a vulnerability to targeting of CDK13 by sgRNA or CDK12/13 inhibitors and treatment of prostate cancer xenograft lines showed that tumors with responded to the CDK12/13 inhibitor SR4835, while CDK12-intact lines did not. Collectively, these studies show that aberrant polyadenylation and long HR gene downregulation is primarily a consequence of acute CDK12 deficiency, which is largely compensated for in cells that have adapted to CDK12 loss. These results provide an explanation for why PARPi monotherapy has thus far failed to consistently benefit patients with CDK12 alterations, though alternate therapies that target CDK13 or transcription are candidates for future research and testing.

CDK12‐inactivation‐induced MYC signaling causes dependency on the splicing kinase SRPK1

Ire1 Alpha Rnase-Dependent Lipid Homeostasis Promotes Survival In Myc-Transformed Cancers

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling

CDK9 inhibition activates innate immune response through viral mimicry

Compromised CDK12 activity causes dependency on the high activity of O-GlcNAc transferase

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13

MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation

Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

B-Raf Activation Cooperates with Pten Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis

Mediator kinase inhibition reverses castration resistance of advanced prostate cancer

Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers

Selective Enhancer Gain of Function Deregulates MYC Expression in Multiple Myeloma

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

Abstract 528: CDK9 inhibition activates innate immune response in prostate cancer cells

Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancer

MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications